Billing codes

The following coverage, coding, and payment information is provided for informational purposes only and should not be construed as legal advice.  The information has been compiled from various resources and is subject to change.  Providers should exercise independent clinical judgment when selecting codes and submitting claims to reflect accurately the services rendered to individual patients.  Third-party payment for medical products and services is affected by numerous factors.  Providers are encouraged to contact third-party payers for specific information on their coverage, coding, and payment policies. 

Biopsy Procedures Codes

Typical ICD-9CM codes

  • 717.9     Unspecified internal derangement – knee
  • 719.96   Unspecified disorder of joint – knee
  • 732.7     Osteochondritis Dissecans
  • 733.90   Disorder of bone & cartilage, unspecified
  • 733.92   Chondromalacia (excludes patella)
  • 836.0     Tear of medial cartilage or meniscus – knee
  • 836.1     Tear of lateral cartilage or meniscus – knee
  • 836.2     Other tear of cartilage or meniscus – knee

Typical CPT* codes used for biopsy

  • 29870 Arthroscopy, knee, diagnostic, with or without synovial biopsy (separate procedure)

Typical concomitant CPT* codes

  • 29874 Arthroscopy, knee, for removal of loose body or foreign body (eg. osteochondritis dissecans fragmentation, chondral fragmentation
  • 29877 Arthroscopy, knee, Debridement/shaving of articular cartilage (chondroplasty)
  • 99070 Supplies and materials (except spectacles) provided by physician over and above those usually included with the office visit or other services rendered (list drugs, trays, supplies or materials provided)

The preceding codes are commonly used to identify the biopsy procedure. If the biopsy was performed as a secondary procedure, remember to use the primary arthroscopic surgical procedure CPT code. Consequently, the insurance provider may down-code any incremental charges associated with taking the biopsy. Incremental charges submitted by the surgeon may be disallowed, and the biopsy may be paid for under a global fee that includes the primary procedure.

CPT codes should be indicated in box 24D on the CMS - 1500 form. 

Autologous Chondrocyte Implantation Codes

Typical ICD-9CM codes

  • 717.9     Unspecified internal derangement - knee
  • 719.96   Unspecified disorder of joint - knee
  • 732.7     Osteochondritis Dissecans
  • 733.90   Disorder of bone & cartilage, unspecified
  • 733.92   Chondromalacia (excludes patella)
  • 836.0     Tear of medial cartilage or meniscus - knee
  • 836.1     Tear of lateral cartilage or meniscus – knee
  • 836.2     Other tear of cartilage or meniscus - knee

CPT Code* :

The American Medical Association (AMA) has issued a unique and permanent Category I CPT Code for autologous chondrocyte implantation (ACI), effective January 1, 2005. The exact terminology is a follows:

27412: Autologous Chondrocyte Implantation, Knee

CPT codes are widely accepted by third party insurers. Please use the above code for CARTICEL implantation.

CPT Modifiers

Physicians may bill modifiers to indicate that a procedure performed has been altered by some specific circumstances, but not changed in its definition or code. Some modifiers that may be appropriate for billing for CARTICEL implantation include:

Modifier 51

When multiple procedures are performed on the same day or at the same operative session, providers should identify the secondary, additional or lesser procedure(s) by adding Modifier 51 to the secondary procedure code(s).

Modifier 22

Providers use Modifier 22 to indicate an unusual procedure was provided greater than that usually required. Additional reimbursement beyond the usual may be made if the payer agrees the procedure involved exceptional circumstances. This modifier may be used for patients with multiple defects, and will trigger manual review of the claim.

Typical concomitant CPT* codes

27418 Anterior tibial tubercleplasty (eg. Maquet type procedure)

  • 29868 Meniscal transplantation (includes arthrotomy for meniscal insertion), medial or lateral
  • 27457 Osteotomy after epiphyseal closure
  • 27428 Intra-articular (open) (ACL repair / reconstruction)

Important notes for physician offices

  • Reimbursement will depend upon the contract with the insurer. The physician may want to consult with the insurer’s contracting representative to determine how the contract may affect reimbursement.
  • CPT Codes should be indicated in box 24D on the CMS – 1500 form.
  • Please note that a listed Category I CPT Code precludes the need for the CMS – 1500 form. In most cases the claim may be filed electronically.

Was this content useful to you?:

Indications and Usage

Carticel® (autologous cultured chondrocytes) is an autologous cellular product indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft).

CARTICEL should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown.

CARTICEL is not indicated for the treatment of cartilage damage associated with generalized osteoarthritis.

CARTICEL is not recommended for patients with total meniscectomy unless surgically reconstructed prior to or concurrent with CARTICEL implantation.

Important Safety Information

CARTICEL should not be used in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides or materials of bovine origin.

It should not be used in patients who have previously had cancer in the bones, cartilage, fat or muscle of the treated limb.

Pre-existing conditions, including meniscal tears, joint instability, or malalignment should be assessed and treated prior to or concurrent with CARTICEL implantation.

CARTICEL is not routinely tested for transmissible infectious diseases and may transmit disease to the healthcare provider handling CARTICEL.

Use of CARTICEL in children, patients over age 65, or in joints other than the knee has not yet been assessed.

The occurrence of subsequent surgical procedures (SSPs), primarily arthroscopy, following CARTICEL implantation is common. In the Study of the Treatment of Articular Repair (STAR), forty-nine percent (49%) of patients underwent an SSP on the treated knee, irrespective of their relationship to CARTICEL, during the 4-year follow up. The most common serious adverse events (≥5% of patients), derived from STAR, include arthrofibrosis/joint adhesions, graft overgrowth, chondromalacia or chondrosis, cartilage injury, graft complication, meniscal lesion, graft delamination, and osteoarthritis.

For more information on CARTICEL, please see the Package Insert (PDF).